Moderate hypofractionated helical tomotherapy for older patients with localized prostate cancer: long-term outcomes of a phase I–II trial

1Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012; 82: e17-24. doi: 10.1016/j.ijrobp.2010.10.075Miralbell R Roberts SA Zubizarreta E Hendry JH Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy Int J Radiat Oncol Biol Phys 2012 15 e17 24 10.1016/j.ijrobp.2010.10.07521324610Open DOISearch in Google Scholar

2Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 2007; 19: 289-301. doi: 10.1016/j. clon.2007.02.007Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 2007 19 289 301 10.1016/j.clon.2007.02.00717517328Open DOISearch in Google Scholar

3Datta NR, Stutz E, Rogers S, Bodis S. Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy. Acta Oncol 2018; 57: 883-94. doi: 10.1080/0284186x.2018.1433874Datta NR Stutz E Rogers S Bodis S Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy Acta Oncol 2018 57 883 94 10.1080/0284186x.2018.143387429405785Open DOISearch in Google Scholar

4Liu HX, Du L, Yu W, Cai BN, Xu SP, Xie CB, et al. Hypofractionated helical tomotherapy for older aged patients with prostate cancer: preliminary results of a Phase I-II trial. Technol Cancer Res Treat 2016; 15: 546-54. doi: 10.1177/1533034615593189Liu HX Du L Yu W Cai BN Xu SP Xie CB et al.Hypofractionated helical tomotherapy for older aged patients with prostate cancer: preliminary results of a Phase I-II trial Technol Cancer Res Treat 2016 15 546 54 10.1177/153303461559318926152749Open DOISearch in Google Scholar

5Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-8. doi: 10.1016/j.ijrobp.2008.02.073Al-Mamgani A van Putten WL Heemsbergen WD van Leenders GJ Slot A Dielwart MF et al.Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 2008 72 980 8 10.1016/j.ijrobp.2008.02.07318495377Open DOISearch in Google Scholar

6Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-60. doi: 10.1016/s1470-2045(16)30102-4Dearnaley D Syndikus I Mossop H Khoo V Birtle A Bloomfield D et al.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Lancet Oncol 2016 17 1047 60 10.1016/s1470-2045(16)30102-4Open DOISearch in Google Scholar

7Roach M, 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 33-7. doi: 10.1016/0360-3016(94)90138-4Roach M MarquezC YuoHS NarayanP ColemanL NseyoUO et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 1994 28 33 7 10.1016/0360-3016(94)90138-47505775Open DOISearch in Google Scholar

8Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-90. doi: 10.1200/ jco.2016.71.7397Catton CN Lukka H Gu CS Martin JM Supiot S Chung PWM et al.Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer J Clin Oncol 2017 35 1884 90 10.1200/jco.2016.71.7397Open DOISearch in Google Scholar

9Roach M, 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11. doi: 10.1200/jco.2003.05.004Roach M DeSilvioM LawtonC UhlV MachtayM SeiderMJ et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 2003 21 1904 11 10.1200/jco.2003.05.00412743142Open DOISearch in Google Scholar

10Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, et al. Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol 2020; 6: 1912-20. doi: 10.1001/jamaoncol.2020.4922Dess RT Suresh K Zelefsky MJ Freedland SJ Mahal BA Cooperberg MR et al.Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate JAMA Oncol 2020 6 1912 20 10.1001/jamaoncol.2020.4922758223233090219Open DOISearch in Google Scholar

11Fine SW. Evolution in prostate cancer staging: Pathology updates from AJCC 8th edition and opportunities that remain. Adv Anat Pathol 2018; 25: 32732. doi: 10.1097/pap.0000000000000200Fine SW Evolution in prostate cancer staging: Pathology updates from AJCC 8th edition and opportunities that remain Adv Anat Pathol 2018 15 199 10.1097/pap.000000000000020029870405Open DOISearch in Google Scholar

12Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6. doi: 10.1016/0360-3016(95)00060-cCox JD Stetz J Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 1995 31 1341 6 10.1016/0360-3016(95)00060-c7713792Open DOISearch in Google Scholar

13Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-6. doi: 10.1016/0197-2456(96)00075-xSchemper M Smith TL A note on quantifying follow-up in studies of failure time Control Clin Trials 1996 17 343 6 10.1016/0197-2456(96)00075-x8889347Open DOISearch in Google Scholar

14Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys 2012; 83: 1473-9. doi: 10.1016/j.ijrobp.2011.10.036Edelman S Liauw SL Rossi PJ Cooper S Jani AB High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes Int J Radiat Oncol Biol Phys 2012 83 1473 9 10.1016/j.ijrobp.2011.10.03622245201Open DOISearch in Google Scholar

15López-Torrecilla J, Pastor-Peidro J, Vicedo-González A, González-Sanchis D, Hernandez-Machancoses A, Almendros-Blanco P, et al. Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy. Clin Transl Oncol 2021; 23: 481-90. doi: 10.1007/s12094-020-02437-0López-Torrecilla J Pastor-Peidro J Vicedo-González A González-Sanchis D Hernandez-Machancoses A Almendros-Blanco P et al.Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy Clin Transl Oncol 2021 23 481 90 10.1007/s12094-020-02437-032621208Open DOISearch in Google Scholar

16Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1949-56. doi: 10.1016/j.ijrobp.2011.04.005Pahlajani N Ruth KJ Buyyounouski MK Chen DY Horwitz EM Hanks GE et al.Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer Int J Radiat Oncol Biol Phys 2012 82 1949 56 10.1016/j.ijrobp.2011.04.005382795721763081Open DOISearch in Google Scholar

17Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 Suppl 1: S29-33. PMID: 16280109Scardino P Update: NCCN prostate cancer Clinical Practice Guidelines J Natl Compr Canc Netw 2005 3 Suppl 1 S29 33 PMID: 16280109Search in Google Scholar

18Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87. doi: 10.1016/s1470-2045(07)70143-2Dearnaley DP Sydes MR Graham JD Aird EG Bottomley D Cowan RA et al.Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 2007 8 475 87 10.1016/s1470-2045(07)70143-217482880Open DOISearch in Google Scholar

19Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 2013; 87: 932-8. doi: 10.1016/j.ijrobp.2013.07.041Michalski JM Yan Y Watkins-Bruner D Bosch WR Winter K Galvin JM et al.Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial Int J Radiat Oncol Biol Phys 2013 87 932 8 10.1016/j.ijrobp.2013.07.041384004424113055Open DOISearch in Google Scholar

20Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol 2018; 4: e180039. doi: 10.1001/jamaoncol.2018.0039MichalskiJM Moughan J PurdyJ BoschW BrunerDW BaharyJP et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial JAMA Oncol 2018 4 e180039 10.1001/jamaoncol.2018.0039588516029543933Open DOISearch in Google Scholar

21Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325-32. doi: 10.1200/jco.2016.67.0448Lee WR Dignam JJ Amin MB Bruner DW Low D Swanson GP et al.Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer J Clin Oncol 2016 34 2325 32 10.1200/jco.2016.67.0448Open DOISearch in Google Scholar

22Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 330-7. doi: 10.1016/j. ijrobp.2007.10.004Cahlon O Zelefsky MJ Shippy A Chan H Fuks Z Yamada Y et al.Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 2008 71 330 7 10.1016/j.ijrobp.2007.10.004 18164858Open DOISearch in Google Scholar

23Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-18. doi: 10.1016/j. ijrobp.2008.10.091Viani GA Stefano EJ Afonso SL Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 2009 74 1405 18 10.1016/j.ijrobp.2008.10.091 19616743Open DOISearch in Google Scholar

24Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer 2016; 122: 2004-11. doi: 10.1002/ cncr.29983Viani GA Viana BS Martin JE Rossi BT Zuliani G Stefano EJ Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial Cancer 2016 122 2004 11 10.1002/cncr.29983 27028170Open DOISearch in Google Scholar

25Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol 2018; 8: 354-60. doi: 10.1016/j.prro.2018.08.002Morgan SC Hoffman K Loblaw DA Buyyounouski MK Patton C Barocas D et al.Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline Pract Radiat Oncol 2018 8 354 60 10.1016/j.prro.2018.08.00230322661Open DOISearch in Google Scholar

26Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1013-21. doi: 10.1016/j. ijrobp.2009.12.045Arcangeli G Fowler J Gomellini S Arcangeli S Saracino B Petrongari MG et al.Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 2011 79 1013 21 10.1016/jijrobp.2009.12.045Open DOISearch in Google Scholar

27Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial. J Clin Oncol 2017; 35: 1891-7. doi: 10.1200/jco.2016.70.4189Arcangeli G Saracino B Arcangeli S Gomellini S Petrongari MG Sanguineti G et al.Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial J Clin Oncol 2017 35 1891 7 10.1200/jco.2016.70.418928355113Open DOISearch in Google Scholar

28Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68: 1424-30. doi: 10.1016/j.ijrobp.2007.01.067Kupelian PA Willoughby TR Reddy CA Klein EA Mahadevan A Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 2007 68 1424 30 10.1016/j.ijrobp.2007.01.06717544601Open DOISearch in Google Scholar

29Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 988-93. doi: 10.1016/s0360-3016(01)01730-8Kupelian PA Reddy CA Klein EA Willoughby TR Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life Int J Radiat Oncol Biol Phys 2001 51 988 93 10.1016/s0360-3016(01)01730-811704322Open DOISearch in Google Scholar

30Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005; 63: 1463-8. doi: 10.1016/j.ijrobp.2005.05.054Kupelian PA Thakkar VV Khuntia D Reddy CA Klein EA Mahadevan A Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes Int J Radiat Oncol Biol Phys 2005 63 1463 8 10.1016/j.ijrobp.2005.05.05416169683Open DOISearch in Google Scholar

31Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31: 3860-8. doi: 10.1200/jco.2013.51.1972Pollack A Walker G Horwitz EM Price R Feigenberg S Konski AA et al.Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer J Clin Oncol 2013 31 3860 8 10.1200/jco.2013.51.1972380592724101042Open DOISearch in Google Scholar

32de Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-Year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys 2020; 106: 108-15. doi: 10.1016/j. ijrobp.2019.09.007de VriesKC WortelRC Oomen-de HoopE HeemsbergenWD PosFJ IncrocciL. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-Year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial Int J Radiat Oncol Biol Phys 2020 106 108 15 10.1016/j.ijrobp.2019.09.007 31593756Open DOISearch in Google Scholar

33Yin Z, You J, Wang Y, Zhao J, Jiang S, Zhang X, et al. Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials. Onco Targets Ther 2019; 12: 1259-68. doi: 10.2147/ott. S181067Yin Z You J Wang Y Zhao J Jiang S Zhang X et al.Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials Onco Targets Ther 2019 12 1259 68 10.2147/ott.S181067 638898030863093Open DOISearch in Google Scholar

34Wen N, Kumarasiri A, Nurushev T, Burmeister J, Xing L, Liu D, et al. An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy. Phys Med Biol 2013; 58: 7733-44. doi: 10.1088/00319155/58/21/7733Wen N Kumarasiri A Nurushev T Burmeister J Xing L Liu D et al.An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy Phys Med Biol 2013 58 7733 44 10.1088/00319155/58/21/7733Open DOISearch in Google Scholar

35Maund IF, Benson RJ, Fairfoul J, Cook J, Huddart R, Poynter A. Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol 2014; 87: 20140459. doi: 10.1259/bjr.20140459Maund IF Benson RJ Fairfoul J Cook J Huddart R Poynter A Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction Br J Radiol 2014 15 199 10.1259/bjr.20140459424319725354015Open DOISearch in Google Scholar

36Utsunomiya S, Yamamoto J, Tanabe S, Oishi M, Satsuma A, Kaidu M, et al. Complementary relation between the improvement of dose delivery technique and PTV margin reduction in dose-escalated radiation therapy for prostate cancer. Pract Radiat Oncol 2019; 9: 172-8. doi: 10.1016/j. prro.2019.02.001Utsunomiya S Yamamoto J Tanabe S Oishi M Satsuma A Kaidu M et al.Complementary relation between the improvement of dose delivery technique and PTV margin reduction in dose-escalated radiation therapy for prostate cancer Pract Radiat Oncol 2019 9 172 8 10.1016/j.prro.2019.02.001 30772440Open DOISearch in Google Scholar

37Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2020; 142: 62-71. doi: 10.1016/j.radonc.2019.10.017Murray J Griffin C Gulliford S Syndikus I Staffurth J Panades M et al.A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer Radiother Oncol 2020 142 62 71 10.1016/j.radonc.2019.10.017700567331767473Open DOISearch in Google Scholar

38Meeks SL, Harmon JF, Jr., Langen KM, Willoughby TR, Wagner TH, Kupelian PA. Performance characterization of megavoltage computed tomography imaging on a helical tomotherapy unit. Med Phys 2005; 32: 2673-81. doi: 10.1118/1.1990289Meeks SL Harmon JF, Jr. LangenKM WilloughbyTR WagnerTH KupelianPA Performance characterization of megavoltage computed tomography imaging on a helical tomotherapy unit Med Phys 2005 32 2673 81 10.1118/1.199028916193798Open DOISearch in Google Scholar

39Murthy V, Krishnatry R, Mallik S, Master Z, Mahantshetty U, Shrivastava S. Helical tomotherapy-based hypofractionated radiotherapy for prostate cancer: a report on the procedure, dosimetry and preliminary clinical outcome. J Cancer Res Ther 2013; 9: 253-60. doi: 10.4103/0973-1482.113378Murthy V Krishnatry R Mallik S Master Z Mahantshetty U Shrivastava S Helical tomotherapy-based hypofractionated radiotherapy for prostate cancer: a report on the procedure, dosimetry and preliminary clinical outcome J Cancer Res Ther 2013 9 253 60 10.4103/0973-1482.11337823771369Open DOISearch in Google Scholar

40Schiller K, Geier M, Duma MN, Nieder C, Molls M, Combs SE, et al. Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients - Long term data on toxicity and biochemical control. Rep Pract Oncol Radiother 2019; 24: 315-21. doi: 10.1016/j.rpor.2019.05.004Schiller K Geier M Duma MN Nieder C Molls M Combs SE et al.Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients - Long term data on toxicity and biochemical control Rep Pract Oncol Radiother 2019 24 315 21 10.1016/j.rpor.2019.05.004654318531193851Open DOISearch in Google Scholar

41Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 2016; 96: 759-69. doi: 10.1016/j. ijrobp.2016.06.2455Pommier P Chabaud S Lagrange JL Richaud P Le Prise E Wagner JP et al.Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study Int J Radiat Oncol Biol Phys 2016 96 759 69 10.1016/j.ijrobp.2016.06.2455 27788949Open DOISearch in Google Scholar

42Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 2018; 19: 1504-15. doi: 10.1016/ s1470-2045(18)30528-xRoach M Moughan J Lawton CAF Dicker AP Zeitzer KL Gore EM et al.Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial Lancet Oncol 2018 19 1504 15 10.1016/s1470-2045(18)30528-x 654079730316827Open DOISearch in Google Scholar

43Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, et al. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. J Cancer Res Clin Oncol 2015; 141: 495-503. doi: 10.1007/s00432-014-1828-7Shiota M Yokomizo A Takeuchi A Imada K Kiyoshima K Inokuchi J et al.The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy J Cancer Res Clin Oncol 2015 141 495 503 10.1007/s00432-014-1828-725227457Open DOISearch in Google Scholar

44Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74: 680-7. doi: 10.1002/pros.22786Kimura K Tsuzuki T Kato M Saito AM Sassa N Ishida R et al.Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens Prostate 2014 74 680 7 10.1002/pros.2278624481730Open DOISearch in Google Scholar

45Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, et al. Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate 2018; 78: 11-6. doi: 10.1002/pros.23438Kato M Kimura K Hirakawa A Kobayashi Y Ishida R Kamihira O et al.Prognostic parameter for high risk prostate cancer patients at initial presentation Prostate 2018 78 11 6 10.1002/pros.2343829094384Open DOISearch in Google Scholar

46Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, et al. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol 2021; 7: 544-52. doi: 10.1001/jamaoncol.2020.7671Feng FY Huang HC Spratt DE Zhao SG Sandler HM Simko JP et al.Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial JAMA Oncol 2021 7 544 52 10.1001/jamaoncol.2020.7671787938533570548Open DOISearch in Google Scholar

47Syrigos KN, Karapanagiotou E, Harrington KJ. Prostate cancer in the elderly. Anticancer Res 2005; 25: 4527-33Syrigos KN Karapanagiotou E Harrington KJ Prostate cancer in the elderly Anticancer Res 2005 15 4527 33Search in Google Scholar

48Wu YH, Yang WC, Hu YW, Hsieh CM, Yang KL, Lai IC, et al. Definitive radiotherapy for older patients with prostate cancer: Experience of a medical center in Taiwan. Sci Rep 2017; 7: 13880. doi:10.1038/s41598-017-13119-3Wu YH Yang WC Hu YW Hsieh CM Yang KL Lai IC et al.Definitive radiotherapy for older patients with prostate cancer: Experience of a medical center in Taiwan Sci Rep 2017 15 199 10.1038/s41598-017-13119-3565567029066834Open DOISearch in Google Scholar

49Dell’Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, et al. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2016; 96: 1037-45. doi: 10.1016/j.ijrobp.2016.05.004Dell’Oglio P Boehm K Trudeau V Tian Z Larcher A Leyh-Bannurah SR et al.Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer Int J Radiat Oncol Biol Phys 2016 96 1037 45 10.1016/j.ijrobp.2016.05.00427478167Open DOISearch in Google Scholar

50Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, et al. The Efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: A subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol Phys 2018; 100: 1179-89. doi: 10.1016/j.ijrobp.2018.01.016Wilson JM Dearnaley DP Syndikus I Khoo V Birtle A Bloomfield D et al.The Efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: A subgroup analysis of the CHHiP trial Int J Radiat Oncol Biol Phys 2018 100 1179 89 10.1016/j.ijrobp.2018.01.016631445229722660Open DOISearch in Google Scholar

51Cuccia F, Fiorentino A, Corrao S, Mortellaro G, Valenti V, Tripoli A, et al. Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes. Aging Clin Exp Res 2020; 32: 747-53. doi: 10.1007/s40520-019-01243-1Cuccia F Fiorentino A Corrao S Mortellaro G Valenti V Tripoli A et al.Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes Aging Clin Exp Res 2020 32 747 53 10.1007/s40520-019-01243-131267377Open DOISearch in Google Scholar

52Sujenthiran A, Parry M, Nossiter J, Berry B, Cathcart PJ, Clarke NW, et al. Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: A National Population-Based Study. Clin Oncol 2020; 32: 501-8. doi: 10.1016/j. clon.2020.02.004Sujenthiran A Parry M Nossiter J Berry B Cathcart PJ Clarke NW et al.Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: A National Population-Based Study Clin Oncol 2020 32 501 8 10.1016/j.clon.2020.02.00432143901Open DOISearch in Google Scholar